Literature DB >> 20089186

Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.

Yu Ri Seo1, Se Hyung Kim, Hyun Jung Kim, Chan Kyu Kim, Seong Kyu Park, Eun Suk Koh, Dae Sik Hong.   

Abstract

No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer (transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin chemotherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy. The patient was still showing a complete response after 4 months. Clinical trials using the FOLFOX regimen as salvage therapy for gemcitabine-refractory advanced urothelial cancer are warranted.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20089186      PMCID： PMC2818621          DOI： 10.1186/1756-8722-3-4

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN： 1756-8722            Impact factor:   17.388


  22 in total

1.  EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma.

Authors:  W Oosterlinck; E Solsona; A P M van der Meijden; R Sylvester; A Böhle; E Rintala; B Lobel
Journal:  Eur Urol       Date:  2004-08       Impact factor: 20.096

2.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; N Geller; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander
Journal:  Cancer       Date:  1989-12-15       Impact factor: 6.860

3.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

Review 4.  Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.

Authors:  B J Roth; D F Bajorin
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

5.  Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

Authors:  W G Harker; F J Meyers; F S Freiha; J M Palmer; L D Shortliffe; J F Hannigan; K M McWhirter; F M Torti
Journal:  J Clin Oncol       Date:  1985-11       Impact factor: 44.544

6.  Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

Authors:  Joaquim Bellmunt; Joan Albanell; Luis Paz-Ares; Miguel A Climent; Jose L González-Larriba; Joan Carles; Juan J de la Cruz; Vicente Guillem; Eduardo Díaz-Rubio; Hernan Cortés-Funes; José Baselga
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

7.  Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.

Authors:  Norma Malavasi; Giovanni Ponti; Roberta Depenni; Federica Bertolini; Sandra Zironi; Gabriele Luppi; Pier Franco Conte
Journal:  J Hematol Oncol       Date:  2009-08-06       Impact factor: 17.388

8.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Authors:  Mace L Rothenberg; Amit M Oza; Robert H Bigelow; Jordan D Berlin; John L Marshall; Ramesh K Ramanathan; Lowell L Hart; Sunil Gupta; Carlos A Garay; Brent G Burger; Nathalie Le Bail; Daniel G Haller
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

Review 9.  Chemotherapy of urothelial tract tumors.

Authors:  A Yagoda
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

10.  Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors.

Authors:  C J Logothetis; E Hossan; A Sella; F H Dexeus; R J Amato
Journal:  J Natl Cancer Inst       Date:  1991-02-20       Impact factor: 13.506
View more
  2 in total

Review 1.  Chemotherapy in advanced bladder cancer: current status and future.

Authors:  Nabil Ismaili; Mounia Amzerin; Aude Flechon
Journal:  J Hematol Oncol       Date:  2011-09-09       Impact factor: 17.388

2.  Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.

Authors:  Takuya Tsujino; Kiyoshi Takahara; Tomohisa Matsunaga; Yuki Yoshikawa; Tomoaki Takai; Taizo Uchimoto; Kenkichi Saito; Naoki Tanda; Hajime Hirano; Hayahito Nomi; Naokazu Ibuki; Teruo Inamoto; Haruhito Azuma
Journal:  J Med Case Rep       Date:  2017-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.